Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study - Scorecard - MDSpire
Advertisement
Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study
Clinical Scorecard: Characterization of lymphoid malignancies based on cellular origin, genetic mutations, and treatment patterns: findings from a comprehensive genome-wide association analysis
At a Glance
Category
Detail
Condition
Lymphoid neoplasms (LNs), a diverse group of malignancies arising from lymphoid cells
Key Mechanisms
Genetic susceptibility involving shared and subtype-specific loci, somatic mutations, cell-of-origin, and drug response profiles
Target Population
Patients with various LN subtypes including CLL, DLBCL, FL, HL, MGUS, MM, MCL, MZL, PTCL, and LPL-WM
Care Setting
Specialized oncology and hematology clinical settings with access to genomic and molecular diagnostics
Key Highlights
LNs comprise over 60 clinically distinct entities with shared genetic susceptibility and familial clustering.
Multi-trait GWAS using phenoclusters based on cell-of-origin, somatic mutations, and drug profiles enhances discovery of genetic risk loci.
Large biobank cohorts (UKB, MVP, FinnGen) with >31,000 LN cases and 1.2 million controls enable meta-analyses of subtype-specific and pleiotropic loci.
Guideline-Based Recommendations
Diagnosis
Incorporate cell-of-origin classification and somatic mutation profiling for LN subtype characterization.
Utilize genomic data from large biobank cohorts to identify genetic risk loci relevant to LN subtypes.
Management
Consider approved therapeutic agents aligned with LN phenoclusters to guide treatment selection.
Leverage genetic and molecular insights to inform personalized therapy approaches.
Monitoring & Follow-up
Apply genetic risk profiling and somatic mutation monitoring to assess disease progression and treatment response.
Risks
Recognize inherited genetic variants, viral infections, environmental exposures, and immune dysregulation as LN risk factors.
Account for pleiotropic genetic effects influencing multiple LN subtypes.
Patient & Prescribing Data
Patients diagnosed with various LN subtypes characterized by genetic and molecular profiles
Drug usage profiles derived from Open Targets indicate approved therapies per LN subtype, supporting phenocluster-informed treatment strategies
Clinical Best Practices
Use hierarchical clustering integrating cell-of-origin, somatic mutations, and drug profiles to define biologically relevant LN phenoclusters.
Employ multi-trait GWAS approaches (phenocluster-based and ASSET) to identify shared and subtype-specific genetic loci.
Validate findings through replication cohorts and functional annotation to prioritize candidate genes and druggable targets.
